Communication from Schering-Plough

Following calls from doctors and a temporary shortage of Trilafon Enanthate (expected deliveries in May), information from Schering-Plough regarding the replacement of the above mentioned product by the tablet form of Trilafon.

For a similar antipsychotic effect:
100mg/21 days of Trilafon Enanthate corresponds to
504 mg Trilafon-tablets (24 mg/day x 21 days)

ie: 3 x daily 1 tbl. Trilafon 8mg for 21 days.

The daily oral dose must be equal to or slightly higher than that given by intramuscular injection, as the drug applied orally has a weaker effect than when administered parenterally.
It is then recommended to reduce the doses to the lowest therapeutically effective oral maintenance dose.

The total oral dose for inpatient treatment should not exceed 64 mg daily.
For outpatient treatment, 24mg per day.

It is best to administer the drug in three equal portions. Once mental status has improved, the dose should be gradually reduced.

Caution:

The switch from Trilafon (tablets) to Trilafon Enanthate
is carried out as follows:
The oral dose is reduced to 16-24 mg/day , followed by a first injection of Trilafon Enanthate in an amount not exceeding 100 mg.
Oral Trilafon should be discontinued on day 2 after the Enanthate injection.

If you have any questions, please contact the Medical Department of
schering-Plough Medical Department:
Warsaw 4 Almond Street
02-796 Warsaw
tel. 022 645 14 94
fax 022 645 12 66

If you experience adverse reactions related to Trilafon therapy, please contact the Medical Department. Fax number given above.